Home Cart Sign in  
Chemical Structure| 83480-29-9 Chemical Structure| 83480-29-9

Structure of Voglibose
CAS No.: 83480-29-9

Chemical Structure| 83480-29-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Voglibose, an N-substituted derivative of valiolamine, can inhibit α-glucosidase and be used to treat hyperglycemia and its concomitant diseases.

Synonyms: AO-128

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Voglibose

CAS No. :83480-29-9
Formula : C10H21NO7
M.W : 267.28
SMILES Code : O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](NC(CO)CO)C1
Synonyms :
AO-128
MDL No. :MFCD00865496
InChI Key :FZNCGRZWXLXZSZ-CIQUZCHMSA-N
Pubchem ID :444020

Safety of Voglibose

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02456428 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02476760 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02685410 HIV Prevention ... More >> STI Prevention Less << Not Applicable Completed - United States, Connecticut ... More >> Yale New Haven Hospital New haven, Connecticut, United States, 06510 Less <<
NCT03157895 Relationship, Family (Foster) ... More >> Substance Use Prevention Less << Not Applicable Recruiting January 31, 2020 United States, Washington ... More >> Social Development Research Group Recruiting Seattle, Washington, United States, 98115 Contact: Jessica Colito, MSW    206-221-5250    jcolito@uw.edu    Contact: Patricia Gomez    206-616-7931    pagomez@uw.edu    Principal Investigator: Kevin Haggerty, PhD          Sub-Investigator: Susan Barkan, PhD Less <<
NCT02475499 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT00985400 Colorectal Cancer Not Applicable Active, not recruiting November 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030-4009 Less <<
NCT00454766 - Active, not recruiting February 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00853203 - Active, not recruiting January 2019 United States, Texas ... More >> Kelsey-Seybold Clinics Houston, Texas, United States, 77030 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01504919 Psychosocial Problem Not Applicable Active, not recruiting January 2019 United States, Texas ... More >> William Marsh Rice University Houston, Texas, United States, 77005 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01311856 - Active, not recruiting March 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00473798 - Active, not recruiting July 2020 United States, Texas ... More >> Hermann Professional Building Clinic Houston, Texas, United States, 77030 LBJ Hospital Houston, Texas, United States, 77030 Texas Medical Center Clinic Houston, Texas, United States, 77030 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, British Columbia Vancouver General Hospital/British Columbia Cancer Agency Vancouver, British Columbia, Canada, V5Z 1M9 Less <<
NCT00533338 Breast Cancer Not Applicable Active, not recruiting July 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01504789 Breast Cancer Not Applicable Active, not recruiting February 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Puerto Rico University of Puerto Rico San Juan, Puerto Rico, 00936 Less <<
NCT02774759 Malignant Neoplasms of Female ... More >>Genital Organs Less << Not Applicable Active, not recruiting October 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00633633 Heart Failure Not Applicable Active, not recruiting February 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78249 Less <<
NCT01697592 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT00501761 - Active, not recruiting May 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01646788 Obstructive Lesions of Arterio... More >>venous Dialysis Fistulae Less << Not Applicable Unknown January 2015 Israel ... More >> The Rabin Medical Center, Hasharon Hospital Not yet recruiting Petah Tikva, Israel Less <<
NCT00542438 Cardiovascular Disease Not Applicable Active, not recruiting October 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02593422 Ovarian Cancer Not Applicable Completed - United States, Maryland ... More >> University of Maryland, College Park College Park, Maryland, United States, 20742 Less <<
NCT02194387 Breast Cancer ... More >> Ovarian Cancer Less << Not Applicable Recruiting September 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT01682824 - Active, not recruiting May 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01242202 Type 2 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Chubu, Japan Hokkaido, Japan Kansai, Japan Kantou, Japan Kyushu, Japan Touhoku, Japan Less <<
NCT01263470 - Completed - -
NCT01697592 - Completed - -
NCT02287402 Impaired Glucose Tolerance (IG... More >>T) Less << PHASE4 COMPLETED 2025-11-12 -
NCT01263470 Diabetes Mellitus, Type 2 Phase 2 Completed - Japan ... More >> Okayama, Japan, 701-0192 Less <<
NCT02287402 Impaired Glucose Tolerance (IG... More >>T) Less << PHASE4 COMPLETED 2025-11-12 -
NCT00724542 Coronary Heart Disease ... More >> Impaired Glucose Tolerance Less << Not Applicable Unknown December 2010 China, Beijing ... More >> Peking University First Hospital Recruiting Beijing, Beijing, China, 100034 Contact: Wenhui Ding, Professor    86-10-66551122 ext 5001    dwh_rd@126.com Less <<
NCT01263496 Type 2 Diabetes Mellitus Phase 2 Completed - -
NCT02097342 Type 2 Diabetes Mellitus ... More >> Insulin Sensitivity/Resistance Less << Phase 4 Unknown January 2015 India ... More >> Postgraduate Institute of Medical Education & Research Recruiting Chandigarh, India, 160012 Contact: Anil Bhansali, MD DM       anilbhansaliendocrine@gmail.com Less <<
NCT00970528 Diabetes Mellitus, Type 2 Phase 4 Completed - Korea, Republic of ... More >> Wonju-si, Gang''weondo, Korea, Republic of, 220-701 Busan, Korea, Korea, Republic of, 602-714 Gyeonggi-do, Korea, Korea, Republic of, 463-500 Gyeonggi-do, Korea, Korea, Republic of, 471-701 Pusan, Korea, Korea, Republic of, 602-739 Seoul, Korea, Korea, Republic of, 150-713 Daegu, Korea, Republic of, 705-717 Jeonju-si, Korea, Republic of, 456-712 Seongbuk-gu Seoul, Korea, Republic of, 136-705 Seoul, Korea, Republic of, 134-701 Seoul, Korea, Republic of, 135-710 Less <<
NCT01263496 - Completed - -
NCT00212017 Impaired Glucose Tolerance ... More >> Myocardial Infarction Less << Not Applicable Terminated(We obtained the fin... More >>al results due to the interim analysis.) Less << - Japan ... More >> National Cardiovascular Center Suita, Osaka, Japan, 565-8565 Less <<
NCT03546972 Obesity and Other Hyperaliment... More >>ation Less << Not Applicable Recruiting November 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       kbasenen@mdanderson.org Less <<
NCT01263483 Type 2 Diabetes Mellitus Phase 2 Phase 3 Completed - -
NCT01263509 Type 2 Diabetes Mellitus Phase 2 Phase 3 Completed - -
NCT01263483 - Completed - -
NCT00411554 Diabetes Mellitus, Non-Insulin... More >>-Dependent Less << Phase 3 Completed - -
NCT01263509 - Completed - -
NCT00411554 - Completed - -
NCT00654381 Diabetes Mellitus, Type 2 Phase 3 Completed - Japan ... More >> 1218.23.05 Boehringer Ingelheim Investigational Site Asahi, Chiba, Japan 1218.23.06 Boehringer Ingelheim Investigational Site Funabashi, Chiba, Japan 1218.23.21 Boehringer Ingelheim Investigational Site Hitachinaka, Ibaraki, Japan 1218.23.44 Boehringer Ingelheim Investigational Site Hitachiota, Ibaraki, Japan 1218.23.09 Boehringer Ingelheim Investigational Site Imizu, Toyama, Japan 1218.23.45 Boehringer Ingelheim Investigational Site Inashiki-gun, Ibaraki, Japan 1218.23.13 Boehringer Ingelheim Investigational Site Izumisano, Osaka, Japan 1218.23.27 Boehringer Ingelheim Investigational Site Kariya, Aichi, Japan 1218.23.47 Boehringer Ingelheim Investigational Site Kitakatsushika-gun, Saitama, Japan 1218.23.39 Boehringer Ingelheim Investigational Site Kitakyuushuu, Fukuoka, Japan 1218.23.02 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 1218.23.03 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 1218.23.10 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 1218.23.37 Boehringer Ingelheim Investigational Site Marugame, Kagawa, Japan 1218.23.38 Boehringer Ingelheim Investigational Site Marugame, Kagawa, Japan 1218.23.23 Boehringer Ingelheim Investigational Site Matsumoto, Nagano, Japan 1218.23.07 Boehringer Ingelheim Investigational Site Meguro-ku, Tokyo, Japan 1218.23.25 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.26 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.28 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.29 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.30 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.04 Boehringer Ingelheim Investigational Site Naka, Ibaraki, Japan 1218.23.15 Boehringer Ingelheim Investigational Site Nishi-ku, Hiroshima, Hiroshima, Japan 1218.23.34 Boehringer Ingelheim Investigational Site Nishi-ku, Sakai, Osaka, Japan 1218.23.22 Boehringer Ingelheim Investigational Site Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan 1218.23.16 Boehringer Ingelheim Investigational Site Oita, Oita, Japan 1218.23.40 Boehringer Ingelheim Investigational Site Oita, Oita, Japan 1218.23.36 Boehringer Ingelheim Investigational Site Okayama, Okayama, Japan 1218.23.11 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.12 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.32 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.33 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.35 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.17 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.18 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.19 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.41 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.42 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.43 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.01 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 1218.23.20 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 1218.23.46 Boehringer Ingelheim Investigational Site Shinjuku-ku, Tokyo, Japan 1218.23.08 Boehringer Ingelheim Investigational Site Shinjyuku-ku,Tokyo, Japan 1218.23.14 Boehringer Ingelheim Investigational Site Suita, Osaka, Japan 1218.23.31 Boehringer Ingelheim Investigational Site Takatsuki, Osaka, Japan 1218.23.48 Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan Less <<
NCT00837577 - Completed - -
NCT01309698 Type 2 Diabetes Phase 4 Completed - Japan ... More >> Novartis Investigative Site Tokyo, Japan Less <<
NCT00654381 - Completed - -
NCT00368134 Diabetes Mellitus, Type 2 Phase 3 Completed - Japan ... More >> Novartis Pharmaceuticals Tokyo, Japan Less <<
NCT01055652 Type 2 Diabetes Mellitus Phase 1 Completed - Japan ... More >> Research Site Moriya, Japan Research Site Osaka, Japan Less <<
NCT02049814 Type 2 Diabetes Mellitus Phase 4 Completed - China, Anhui ... More >> Hefei, Anhui, China Maanshan, Anhui, China China, Beijing Beijing, Beijing, China China, Guangdong Guangzhou, Guangdong, China Shenzhen, Guangdong, China Taishan, Guangdong, China China, Hunan Zhuzhou, Hunan, China China, Jiangsu Nanjing, Jiangsu, China Xuzhou, Jiangsu, China China, Jilin Changchun, Jilin, China Jilin, Jilin, China China, Liaoning Shenyang, Liaoning, China China, Shandong Qingdao, Shandong, China China, Shanghai Shanghai, Shanghai, China China, Shanxi Yan An, Shanxi, China Yanan, Shanxi, China China, Tianjin Tianjin, Tianjin, China China, Zhejiang Wenzhou, Zhejiang, China Less <<
NCT01993927 Impaired Glucose Tolerance COMPLETED 2013-08-31 Osaka, Japan
NCT01993927 Impaired Glucose Tolerance COMPLETED 2013-08-31 Osaka, Japan
NCT00663884 Diabetes Mellitus, Type 2 Phase 4 Completed - Korea, Republic of ... More >> The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital Seoul, Korea, Republic of, 137-701 Less <<
NCT00837577 Diabetes Mellitus, Non-Insulin... More >>-Dependent Less << Phase 3 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.74mL

0.75mL

0.37mL

18.71mL

3.74mL

1.87mL

37.41mL

7.48mL

3.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories